VirTus Respiratory Research Supports Development of Apollo Therapeutics’ APL-10456 from Preclinical Proof of Concept to Positive Phase 1 Data

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire VirTus Respiratory Research Supports Development of Apollo Therapeutics' APL-10456 from Preclinical Proof of Concept to Positive Phase 1 DataAuthor of the article:THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountLONDON — VirTus Respiratory Research Ltd, a specialist respiratory contract research organisation (CRO), founded by Imperial College London investigators Professor Sebastian Johnston and Dr Michael Edwards, today highlighted its role in the preclinical development of Apollo Therapeutics’ and Imperial’s APL-10456, following the announcement of positive initial data from the vaccine’s Phase 1 clinical trial.VirTus has worked on the APL-10456 programme for more than five years, conducting more than 20 preclinical studies to support the selection, development and progression of the candidate, testing the cross-species immunogenicity and efficacy. This work included evaluating the efficacy of several vaccine candidates in mouse models of rhinovirus infection, helping to select APL-10456 and establish early proof of concept and generating preclinical evidence that informed its progression into first-in-human clinical development.APL-10456 is a first-in-class, adjuvanted recombinant protein subunit vaccine designed to prevent rhinovirus-driven exacerbations of chronic obstructive pulmonary disease (COPD) and asthma. Developing a broadly protective rhinovirus vaccine has historically been challenging because of the approximately 180 genetically distinct rhinovirus strains across three species – RV-A, RV-B and RV-C.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againApollo has announced that enrolment and dosing in the randomised, double-blind, placebo-controlled Phase 1 study of APL-10456, involving 144 healthy participants, has completed. Initial data from Part A of the study showed that a single dose was well tolerated and highly immunogenic, inducing seroconversion and Th1-polarised, cross-reactive cellular immune responses against all three rhinovirus species.These first-in-human findings are consistent with previously reported preclinical data demonstrating broad cross-strain immunity and rapid clearance of heterotypic rhinovirus, and represent an important milestone in the translation of the APL-10456 programme from preclinical research into clinical development.Professor Sebastian Johnston, Co-Founder and Chief Medical Officer of VirTus Respiratory Research, and Professor of Respiratory Medicine & Allergy at Imperial College London’s National Heart and Lung Institute, said:“Rhinovirus infections have remained an elusive target for vaccine development due to the ~180 antigenically different strains, despite the substantial burden they place on people with asthma and COPD. After our pivotal preclinical studies at VirTus, it is hugely encouraging to see APL-10456 now generating promising clinical data in man, and we are proud to have contributed to the programme’s development. This is exactly the kind of translational research we set VirTus up to support.”The progression of APL-10456 demonstrates VirTus’s ability to support respiratory drug and vaccine development from early preclinical studies, to proof of concept, using specialist models of respiratory viral infection to help evaluate promising therapeutic approaches before they enter human studies.VirTus Respiratory Research Ltd is a CRO co-led by Professor Sebastian Johnston and Dr Michael Edwards, both of Imperial College London, United Kingdom. VirTus is dedicated to accelerating the development of novel therapies for the treatment and prevention of respiratory virus infections, which are the leading cause of acute attacks (exacerbations) in chronic respiratory diseases such as asthma, COPD and bronchiectasis. VirTus conducts both pre-clinical and early-phase clinical studies, specialising in preclinical studies and human virus challenge models to generate high-quality data that supports the advancement of new therapeutics into later-stage development.Rhinovirus infection is the most common cause of viral respiratory infection worldwide and the leading cause of the common cold. While typically mild in healthy individuals, rhinovirus infection is a major driver of exacerbations in chronic respiratory diseases such as asthma and COPD, leading to increased morbidity and healthcare utilisation. Despite its significant clinical impact, there are currently no approved targeted antiviral therapies or vaccines for rhinovirus infection, highlighting a substantial unmet medical need.About Imperial College LondonWe are Imperial – a world-leading university for science, technology, engineering, medicine and business (STEMB), where scientific imagination leads to world-changing impact.As a global top ten university in London, we use science to try to understand more of the universe and improve the lives of more people in it. Across our nine campuses and throughout our Imperial Global network, our 22,000 students, 8,000 staff, and partners work together on scientific discovery, innovation and entrepreneurship. Their work navigates some of the world’s toughest challenges in global health, climate change, AI, business leadership and more.Founded in 1907, Imperial’s future builds on a distinguished past, having pioneered penicillin, holography and fibre optics. Today, Imperial combines exceptional teaching, world-class facilities and a habit of interdisciplinary practice to unlock scientific imagination.View source version on businesswire.com: This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.